Ferrer: Ferrer's progressive supranuclear palsy therapy gains FDA fast track status
In-licensed from Asceneuron, this new molecular entity is currently undergoing a Phase II trial. The trial aims to assess the therapy's efficacy, pharmacokinetics, and safety in adults diagnosed The post Ferrer's progressive supranuclear palsy therapy gains FDA fast track status appeared first on Pharmaceutical Business review.
Read full article »
Ferrer is a fully vertically integrated pharmaceutical firm from research and development, through manufacturing, to sales and distribution.
Read more